Evidence map›Paper›PMID 29459399›Full record

Trial reportStroke2018

External Validation of Risk Scores for Major Bleeding in a Population-Based Cohort of Transient Ischemic Attack and Ischemic Stroke Patients.

Nina A Hilkens, Linxin Li, Peter M Rothwell, Ale Algra, Jacoba P Greving

Open access · hybridAbstract readClinical TrialComparative StudyMulticenter Study

In one paragraph

Trial report in Stroke, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it

0cells of the map it votes in

5citing papers in PubMed

1.7field-weighted citation impact, top 15% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia.Scientific reports · 2023
Trial
Role of cerebral microbleeds in acute ischemic stroke and atrial fibrillation.Journal of thrombosis and thrombolysis · 2023
Review
Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.Stroke · 2021
Article
In-hospital prognosis of first-ever noncardiogenic ischemic stroke in patients with and without indication for prestroke antiplatelet therapy: Chinese Stroke Center Alliance.Annals of translational medicine · 2021
Article
Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence.Thrombosis and haemostasis · 2018
Review

4 · The record

Corrections and comments

Commented on by
Charting the Course: Risk Scores for Major Bleeding in Transient Ischemic Attack and Ischemic Stroke.2018

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Nina A HilkensFrom the Julius Center for Health Sciences and Primary Care (N.A.H., A.A., J.P.G.) and Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus (A.A.), University Medical Center Utrecht, Utrecht University, the Netherlands; and Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom (L.L., P.M.R.). n.a.hilkens-3@umcutrecht.nl.

Linxin LiFrom the Julius Center for Health Sciences and Primary Care (N.A.H., A.A., J.P.G.) and Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus (A.A.), University Medical Center Utrecht, Utrecht University, the Netherlands; and Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom (L.L., P.M.R.).

Peter M RothwellFrom the Julius Center for Health Sciences and Primary Care (N.A.H., A.A., J.P.G.) and Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus (A.A.), University Medical Center Utrecht, Utrecht University, the Netherlands; and Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom (L.L., P.M.R.).

Ale AlgraFrom the Julius Center for Health Sciences and Primary Care (N.A.H., A.A., J.P.G.) and Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus (A.A.), University Medical Center Utrecht, Utrecht University, the Netherlands; and Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom (L.L., P.M.R.).

Jacoba P GrevingFrom the Julius Center for Health Sciences and Primary Care (N.A.H., A.A., J.P.G.) and Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus (A.A.), University Medical Center Utrecht, Utrecht University, the Netherlands; and Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom (L.L., P.M.R.).

Nuffield Orthopaedic Centre · GB

Funding

Wellcome Trust

6 · The paper itself

Abstract

background and purposeThe S

methodsWe studied risk of bleeding in 2072 patients with a transient ischemic attack or ischemic stroke on antiplatelet agents in the population-based OXVASC (Oxford Vascular Study) according to 3 scores: S

resultsDuring 8302 patient-years of follow-up, 117 patients had a major bleed. The S

conclusionsThe S

Indexed as

Brain IschemiaHemorrhagePlatelet Aggregation InhibitorsStrokeAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedRisk FactorsPlatelet Aggregation Inhibitorsantiplatelet agentsbleedinghumanriskstroke

Identifiers

PMID29459399

DOI10.1161/STROKEAHA.117.019259

PMCPMC5839707

OpenAlexW2788943097

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.